Contents
Share
Methotrexate (MTX) is a first-line treatment in the fight against rheumatoid arthritis (RA)—an autoimmune disease characterized by joint deterioration. However, the precise therapeutic mechanisms of MTX are poorly understood. Now, researchers from Chiba University reveal that a variant of tumor protein p63, TAp63, is suppressed by MTX, which in turn suppresses the expression of another protein, Foxp3, and aggravates RA.
